, Figure III.5.7 -Time Variation -YPLL80
, Note -This figure shows how Years of Potential Life Lost (age reference = 80) varies depending on the length of time to drug launch. The model includes disease fixed effects and year fixed effects. The graph includes 90% two-sided confidence intervals. Orphan Drugs and Longevity in the US
, name ICD-10, Disease name ICD-10, 1999.
, Orphan Drugs and Longevity in the US Revisited name ICD-10, 1999.
, publication_dates = open('publication_dates.csv', 'w') for code_maladie
The European Organization for Research and Treatment of Cancer QLQ-Cc30: A quality-of-life instrument for use in international clinical trials in oncology, JNCI: Journal of the National Cancer Institute, vol.85, issue.5, p.43, 1993. ,
The relationship between health and growth: When Lucas meets Nelson-Phelps, p.157, 2010. ,
Interaction terms in logit and probit models, Economics letters, vol.80, issue.1, pp.123-129, 2003. ,
Rapport d'activité 2016 de l'alliance maladies rares, vol.58, 2016. ,
Subjective unmet need and utilization of health care services in Canada: What are the equity implications?, Social Science & Medicine, vol.70, issue.3, pp.465-472, 2010. ,
The personal costs of caring for a child with a disability: A review of the literature, Public Health Reports, vol.122, issue.1, pp.3-16, 2007. ,
Predicting health behaviors with an experimental measure of risk preference, Journal of Health Economics, vol.27, issue.5, p.61, 2008. ,
Priority setting for pharmaceuticals, The European Journal of Health Economics, formerly: HEPAC, vol.5, issue.1, pp.28-35, 2004. ,
Mostly harmless econometrics: An empiricist's companion, p.136, 2008. ,
Some tests of specification for panel data: Monte carlo evidence and an application to employment equations, The Review of Economic Studies, vol.58, issue.2, pp.277-297, 1991. ,
Mesurer les préférences desépargnants: comment et pourquoi (en temps de crise, Economie et Statistique, vol.467, pp.5-49, 2014. ,
Inégalités patrimoniales et choix individuels: des goûts et des richesses, p.65, 2007. ,
Mesurer les préférences individuellesà l'égard du risque, Économie et Statistique, vol.374, issue.1, pp.53-85, 2004. ,
,
Préférences de l'épargnant et accumulation patrimoniale, Economie et Statistique, vol.5, pp.374-375, 2004. ,
Uncertainty and the welfare economics of medical care: Reply (The implications of transaction costs and adjustment lags), The American Economic Review, vol.55, issue.1, pp.154-158, 1963. ,
Outsourcing at will: The contribution of unjust dismissal doctrine to the growth of employment outsourcing, Journal of Labor Economics, vol.21, issue.1, pp.1-42, 2003. ,
The problem of rarity: Estimation of prevalence in rare disease, Value in Health, vol.21, issue.5, p.45, 2018. ,
Consistent estimation of the fixed effects ordered logit model, Journal of the Royal Statistical Society: Series A (Statistics in Society), vol.178, issue.3, pp.685-703, 2015. ,
The productivity of physician specialization: Evidence from the medicare program, American Economic Review, vol.94, issue.2, pp.357-361, 2004. ,
What's the delay? A qualitative study of women's experiences of reaching a diagnosis of endometriosis, Fertility and Sterility, vol.86, issue.5, p.40, 2006. ,
Prejudice, clinical uncertainty and stereotyping as sources of health disparities, Journal of health economics, vol.22, issue.1, pp.89-116, 2003. ,
Testing for statistical discrimination in health care, Health Services Research, vol.40, issue.1, pp.227-252, 2005. ,
Developmental origins of non-communicable disease: Implications for research and public health, Environmental Health, vol.11, issue.1, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00712586
Implications of spillover effects within the family for medical costeffectiveness analysis, Journal of Health Economics, vol.24, issue.4, pp.751-773, 2005. ,
Emergence of pediatric rare diseases. Rare Diseases, 1, vol.170, p.254, 2013. ,
The rare and undiagnosed diseases diagnostic service-application of massively parallel sequencing in a state-wide clinical service, Orphanet Journal of Rare Diseases, vol.11, issue.1, 2016. ,
A theory of social interactions, Journal of Political Economy, vol.82, issue.6, pp.1063-1093, 1974. ,
Les convergences parallèles: uneéconomie politique de la régulation de l'accès au marché des médicaments en France et en Angleterre, vol.249, p.250, 2016. ,
Utilitarianism and Other Essays, 2004. ,
Collecting retrospective data: accuracy of recall after 50 years judged against historical records, Social Science & Medicine, vol.45, issue.10, pp.1519-1525, 1997. ,
Fertility, employment, and child-care costs, Demography, vol.26, issue.2, pp.287-299, 1989. ,
The doctor as double agent: Information asymmetry, health insurance, and medical care, Journal of Health Economics, vol.10, issue.4, pp.411-432, 1991. ,
Alternative approaches to evaluation in empirical microeconomics, Portuguese Economic Journal, vol.1, issue.2, pp.91-115, 2002. ,
Caring for and caring about: Disentangling the caregiver effect and the family effect, Journal of Health Economics, vol.29, issue.4, pp.549-556, 2010. ,
Health effects of caring for and about parents and spouses. Tinbergen Institute Discussion Papers 18-050/V, Tinbergen Institute, p.96, 2018. ,
Race, ethnicity, and pain treatment: Striving to understand the causes and solutions to the disparities in pain treatment, The Journal of Law, vol.28, issue.4, p.69, 2001. ,
Does informal care from children to their elderly parents substitute for formal care in Europe, Journal of Health Economics, vol.28, issue.1, pp.143-154, 2009. ,
Assessing the gold standard -Lessons from the history of RCTs, New England Journal of Medicine, vol.374, p.48, 2016. ,
Le capital social. Actes de la recherche en sciences sociales, vol.31, 1980. ,
Rare-disease genetics in the era of next-generation sequencing: Discovery to translation, Nature Reviews Genetics, vol.14, issue.10, p.46, 2013. ,
, Gender differences in altruism: Expectations, actual behaviour and accuracy of beliefs, 2016.
Gender differences in altruism on mechanical turk: Expectations and actual behaviour, Economics Letters, vol.170, pp.19-23, 2018. ,
Social inequalities in health within countries: Not only an issue for affluent nations, Social Science & Medicine, vol.54, issue.11, p.42, 2002. ,
Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing: a report of the main survey, vol.157, 2013. ,
Clinical trials of orphan medicines, The Lancet, vol.371, issue.9629, p.124, 2008. ,
Commentary: Tonsillectomy-Then and now, International Journal of Epidemiology, vol.37, issue.1, pp.23-25, 2008. ,
Health status of caregivers of children with cerebral palsy. Child: Care, Health and Development, vol.36, pp.696-702, 2010. ,
Quality of life in caregivers of patients with schizophrenia: A literature review, Health and Quality of Life Outcomes, vol.7, issue.1, p.86, 2009. ,
Benefit payments, informal care and female labour supply, Applied Economics Letters, vol.10, issue.7, pp.411-415, 2003. ,
Characterizing the drug development pipeline for precision medicines, National Bureau of Economic Research, vol.30, p.125, 2017. ,
Patient cost-sharing and hospitalization offsets in the elderly, American Economic Review, vol.100, issue.1, pp.193-213, 2010. ,
Physicians and implicit bias: How doctors may unwittingly perpetuate health care disparities, Journal of General Internal Medicine, vol.28, issue.11, 2013. ,
Experimental methods: Eliciting risk preferences, Journal of Economic Behavior & Organization, vol.87, p.61, 2013. ,
The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature, Radiotherapy and Oncology, vol.87, issue.1, p.42, 2008. ,
Costs and healthrelated quality of life of patients with cystic fibrosis and their carers in france, Journal of Cystic Fibrosis, vol.14, issue.3, p.43, 2015. ,
Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample, American Journal of Psychiatry, vol.159, issue.11, pp.1862-1868, 2002. ,
The role of health technology assessment bodies in shaping drug development. Drug Design, Development and Therapy, vol.8, p.48, 2014. ,
Do health changes affect smoking? Evidence from British panel data, Journal of Health Economics, vol.21, issue.4, pp.533-562, 2002. ,
Methods for the estimation of the N|ational Institute for Health and Care Excellence cost-effectiveness threshold, Health Technology Assessment, vol.19, issue.14, p.250, 2015. ,
Methods for the estimation of the NICE cost effectiveness threshold, vol.244, p.248, 2013. ,
Causes for concern: Is NICE failing to uphold its responsibilities to all NHS patients?, Health Economics, vol.24, issue.1, pp.1-7, 2015. ,
The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics, p.248, 2018. ,
Is the Pharmaceutical Industry in a Productivity Crisis? Chapter, p.139, 2007. ,
What is the value of oncology medicines?, Nature Biotechnology, vol.28, issue.11, pp.1160-1163, 2010. ,
Social relationships and health, American Pychologist, vol.59, issue.8, 2004. ,
Social capital in the creation of human capital, American Journal of Sociology, vol.94, 1988. ,
Principles of justice in health care rationing, Journal of Medical Ethics, vol.26, issue.5, pp.323-329, 2000. ,
Patients' perspectives on diabetes health care education, Health Education Research, vol.18, issue.2, pp.191-206, 2003. ,
Mothers' labor supply in fragile families: The role of child health, Eastern Economic Journal, vol.31, issue.4, pp.601-616, 2005. ,
Who interacts on the Web?: The intersection of users' personality and social media use, Computers in Human Behavior, vol.26, issue.2, pp.247-253, 2010. ,
What is wrong with orphan drug policies? Value in Health, vol.15, p.50, 2012. ,
Regression models and life-tables, Breakthroughs in Statistics, pp.527-541, 1992. ,
, , p.66
Does father care mean fathers share? A comparison of how mothers and fathers in intact families spend time with children, Gender & Society, vol.20, issue.2, pp.259-281, 2006. ,
Healthy, wealthy, and wise: Socioeconomic status, poor health in childhood, and human capital development, Journal of Economic Literature, vol.47, issue.1, pp.87-122, 2009. ,
Understanding differences in health behaviors by education, Journal of Health Economics, vol.29, issue.1, pp.1-28, 2010. ,
The influence of costeffectiveness and other factors on nice decisions, Health Economics, vol.24, issue.10, p.249, 2015. ,
, Progress in rare diseases research 2010-2016: An IRDiRC perspective, vol.11, 2018.
Two-way fixed effects estimators with heterogeneous treatment effects, 2018. ,
Does education affect smoking behaviors?: Evidence using the Vietnam draft as an instrument for college education, Journal of Health Economics, vol.26, issue.5, pp.877-895, 2007. ,
Maternal education and child health: Is there a strong causal relationship? Demography, vol.35, pp.71-81, 1998. ,
Le renoncement aux soins pour raisons financières: une approcheéconométrique. Irdes, Questions d'économie de la santé, vol.170, p.60, 2011. ,
Hétérogénéité sociale de déclaration de l'état de santé et mesure des inégalités de santé, Revue française des affaires sociales, vol.87, pp.29-47, 2008. ,
Forced to be rich? Returns to compulsory schooling in Britain, The Economic Journal, vol.120, issue.549, pp.1345-1364, 2010. ,
Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Economics, vol.13, issue.5, pp.437-452, 2004. ,
Does social capital determine health? Evidence from eight transition countries, Health Economics, vol.19, issue.1, p.61, 2010. ,
The image of health: Variations in perception by social class in a French population, Sociology of Health & Illness, vol.6, issue.1, p.69, 1984. ,
Parental altruism and the value of avoiding acute illness: Are kids worth more than parents, Journal of Environmental Economics and Management, vol.48, issue.3, pp.1146-1174, 2004. ,
Caregivers for Alzheimer's patients: What we are learning from research, The International Journal of Aging and Human Development, vol.30, issue.4, pp.263-285, 1990. ,
Innovation in the pharmaceutical industry: New estimates of R&D costs, Journal of Health Economics, vol.47, pp.20-33, 2016. ,
The price of innovation: New estimates of drug development costs, Journal of Health Economics, vol.22, issue.2, p.129, 2003. ,
Did it matter that the cancer drugs fund was not NICE? A retrospective review, Value in Health, vol.19, issue.6, pp.879-884, 2016. ,
Does self-assessed health measure health?, Applied Economics, vol.47, issue.2, pp.180-194, 2015. ,
Thinking about it: thoughts about health and valuing qalys, Health Economics, vol.20, issue.12, pp.1407-1416, 2011. ,
Who cooperates in repeated games: The role of altruism, inequity aversion, and demographics, Journal of Economic Behavior & Organization, vol.98, pp.41-55, 2014. ,
Orphan drugs policies: A suitable case for treatment: Editorial, European Journal of Health Economics, vol.15, issue.4, pp.335-340, 2014. ,
Assessing the economic challenges posed by orphan drugs, International journal of technology assessment in health care, vol.23, issue.1, pp.36-42, 2007. ,
Market size and pharmaceutical innovation, The RAND Journal of Economics, vol.46, issue.4, pp.844-871, 2015. ,
Reciprocity, elder satisfaction, and caregiver stress and burden: The exchange of aid in the family caregiving relationship, Journal of Marriage and the Family, vol.27, p.43, 1994. ,
European medicines agency. committee for medicinal products for human use, vol.29, p.45, 2013. ,
Delay versus help seeking for breast cancer symptoms: a critical review of the literature on patient and provider delay, Social Science & Medicine, vol.36, issue.12, pp.1521-1534, 1993. ,
Difficultés diagnostiques de l'hémochromatose génétique hfe (retard, excès, absence): point de vue du malade, Annales de Biologie Clinique, vol.70, pp.492-495, 2012. ,
Profile of Rare Diseases, p.152, 2010. ,
Static and dynamic effects of health policy: Evidence from the vaccine industry, The Quarterly Journal of Economics, vol.119, issue.2, pp.527-564, 2004. ,
Providing care for an elderly parent: interactions among siblings? Health economics, vol.18, pp.1011-1029, 2009. ,
The quality of gp diagnosis and referral, p.70, 2010. ,
Primary care: a critical review of the evidence on quality and costs of health care, vol.29, pp.766-772, 2010. ,
Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study, Bmj, vol.326, issue.7382, 2003. ,
Risk attitude and time preference in health, Management Science, vol.30, issue.4, p.61, 1984. ,
A theory of intergenerational altruism, Econometrica, vol.85, issue.4, pp.1175-1218, 2017. ,
Institutions, health shocks and labour market outcomes across Europe, Journal of Health Economics, vol.30, issue.1, p.95, 2011. ,
Health shocks, employment and income in the Spanish labour market, Health Economics, vol.15, issue.9, pp.997-1009, 2006. ,
Long-term and spillover effects of health shocks on employment and income, Journal of Human Resources, vol.48, issue.4, pp.873-909, 2013. ,
Toward a broader concept of value: Identifying and defining elements for an expanded cost-effectiveness analysis, Value in Health, vol.20, issue.2, pp.213-216, 2017. ,
Linking pharmacogenetics-based diagnostics and drugs for personalized medicine, vol.25, pp.1281-1290, 2006. ,
, , 2005.
, Prevalence and treatment of psoriasis in the United Kingdom: A population-based study, Archives of Dermatology, vol.141, issue.12, pp.1537-1541
Neighborhood socioeconomic context and long-term survival after myocardial infarction, Circulation, vol.121, issue.3, pp.375-383, 2010. ,
Ethical issues in funding orphan drug research and development, Journal of Medical Ethics, vol.31, issue.3, pp.164-168, 2005. ,
Do conditional cash transfers improve child health? Evidence from PROGRESA's control randomized experiment, American Economic Review, vol.94, issue.2, pp.336-341, 2004. ,
Orphan medicinal products in europe and united states to cover needs of patients with rare diseases: an increased common effort is to be foreseen, Orphanet Journal of Rare Diseases, issue.1, p.12, 2017. ,
Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: An increased common effort is to be foreseen, Orphanet Journal of Rare Diseases, vol.12, issue.1, p.125, 2017. ,
An economic approach to social capital, The Economic Journal, issue.483, p.61, 2002. ,
The incidence of tonsillectomy in school children, International Journal of Epidemiology, vol.37, issue.1, p.57, 2008. ,
Les déterminants sociaux de la santé: apports récents de l'épidémiologie sociale et des sciences sociales de la santé, Sciences sociales et santé, vol.20, issue.4, pp.75-128, 2002. ,
The increasing value of education to health, Social Science & Medicine, vol.72, issue.10, pp.1728-1737, 2011. ,
Can patient self-management help explain the SES health gradient, Proceedings of the National Academy of Sciences, vol.99, pp.10929-10934, 2002. ,
Manic-depressive illness: Bipolar disorders and recurrent depression, vol.1, p.64, 2007. ,
The effectiveness of social marketing interventions for health improvement: What's the evidence? Public Health, vol.120, pp.1133-1139, 2006. ,
Orphan drug designations as valuable intangible assets for ipo investors in pharma-biotech companies, Economic Dimensions of Personalized and Precision Medicine, vol.33, p.50, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02152424
Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companies, Economic Dimensions of Personalized and Precision Medicine, p.140, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02152424
Decomposing the effects of children's health on mother's labor supply: Is it time or money? Health Economics, vol.13, p.97, 2004. ,
L'enquête sur le recours au spécialiste en médecine de ville en 2007. DREES, document de travail, vol.69, pp.1-173, 2010. ,
Hedonic capital, adaptation and resilience, Journal of Economic Behavior & Organization, vol.76, issue.2, pp.372-384, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00870190
Counting the costs of cancer, vol.85, 2011. ,
Alpha1-antitrypsin deficiency-diagnostic testing and disease awareness in Germany and Italy, Respiratory Medicine, vol.107, issue.9, p.45, 2013. ,
Clinical research for rare disease: Opportunities, challenges, and solutions, Molecular Genetics and Metabolism, vol.96, issue.1, p.202, 2009. ,
Strengthening weak primary care systems: Steps towards stronger primary care in selected Western and Eastern European countries, Health Policy, vol.113, issue.1, pp.170-179, 2013. ,
On the concept of health capital and the demand for health, Journal of Political Economy, vol.80, issue.2, pp.223-255, 1972. ,
Perceived health and adaptation in chronic disease, vol.87, 2017. ,
Social capital and health interventions: Enhancing social capital to improve health. In Elgar Companion to Social Capital and Health, p.253, 2018. ,
URL : https://hal.archives-ouvertes.fr/halshs-01885679
Delay in the diagnosis of endometriosis: A survey of women from the USA and the UK, Human Reproduction, vol.11, issue.4, p.40, 1996. ,
, Rapport de mandature de la commissionévaluationéconomique et santé publique, HAS, p.242, 2018.
Behavior problems of children with autism, parental self-efficacy, and mental health, American Journal on Mental Retardation, vol.107, issue.3, pp.222-232, 2002. ,
Bipolar disorder: Diagnosis, Swiss Medical Forum/Schweizerisches Medizin-Forum, vol.9, issue.42, p.64, 2009. ,
Social capital and health promotion: A review, Social Science & Medicine, vol.51, issue.6, p.61, 2000. ,
The economics and econometrics of active labor market programs, Handbook of Labor Economics, vol.3, p.92, 1999. ,
Drugs for exceptionally rare diseases: Do they deserve special status for funding?, QJM, vol.98, issue.11, pp.829-836, 2005. ,
Profitability and market value of orphan drug companies: A retrospective, propensity-matched case-control study, PLOS One, vol.11, issue.10, p.46, 2016. ,
Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM, An International Journal of Medicine, vol.98, issue.11, pp.829-836, 2005. ,
Educational attainment and adult mortality, International Handbook of Adult Mortality, p.58, 2011. ,
Self-rated health and mortality: A review of twenty-seven community studies, Journal of Health and Social Behavior, vol.87, pp.21-37, 1997. ,
Recent developments in the econometrics of program evaluation, Journal of Economic Literature, vol.47, issue.1, pp.5-86, 2009. ,
Disease management index of potential years of life lost as a tool for setting priorities in national disease control using OECD health data, Health Policy, vol.115, issue.1, p.203, 2014. ,
Estimating the clinical cost of drug development for orphan versus non-orphan drugs, Orphanet Journal of Rare Diseases, vol.14, issue.1, 2019. ,
Evaluation médico-économique en santé. Rapport Inspection générale des affaires sociales, vol.243, p.244, 2014. ,
Tumor progression in waiting time for radiotherapy in head and neck cancer, Radiotherapy and Oncology, vol.84, issue.1, p.42, 2007. ,
Delays in referral of soft tissue sarcomas, Sarcoma, p.70, 2008. ,
Education and health knowledge: Evidence from UK compulsory schooling reform, Social Science & Medicine, vol.127, pp.92-100, 2015. ,
Clinical trials in children, British Journal of Clinical Pharmacology, vol.79, issue.3, pp.357-369, 2015. ,
The role of time and risk preferences in smoking inequalities: A population-based study, Addictive Behaviors, vol.38, issue.5, p.65, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01526058
Circumstances and efforts: How important is their correlation for the measurement of inequality of opportunity in health?, Health Economics, vol.22, issue.12, pp.1470-1495, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01526037
Representativeness revisited: Attribute substitution in intuitive judgment, Heuristics and Biases: The Psychology of Intuitive Judgment, vol.49, p.61, 2002. ,
The political economy of the assessment of value of new health technologies, pp.1355819617751816-248, 2018. ,
Social capital and health. Social Capital and Health, vol.58, pp.1-26, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-01471470
Do general practitioners overestimate the health of their patients with lower education?, Social Science & Medicine, vol.73, issue.9, pp.1416-1421, 2011. ,
Health behavior, health knowledge, and schooling, Journal of Political Economy, vol.99, issue.2, pp.287-305, 1991. ,
Appraising the value of innovation and other benefits. A short study for NICE, p.246, 2009. ,
,
The role of coping in maintaining the psychological well-being of mothers of adults with intellectual disability and mental illness, Journal of Intellectual Disability Research, vol.47, issue.4-5, pp.313-327, 2003. ,
Making sense of two-sided altruism, Journal of Monetary Economics, vol.20, issue.2, pp.301-326, 1987. ,
Variations in population health status: Results from a United Kingdom national questionnaire survey, British Medical Journal, vol.316, issue.7133, p.43, 1998. ,
Inequalities in parental spending on young children, AERA Open, vol.2, issue.2, 1972. ,
Is hospital care involved in inequalities in coronary heart disease mortality? Results from the french WHO-MONICA Project in men aged 30-64, Journal of Epidemiology & Community Health, vol.52, issue.10, pp.665-671, 1998. ,
Social determinants of cardiovascular diseases, Public Health Reviews, vol.33, issue.2, 2011. ,
Estimation of panel data models with binary indicators when treatment effects are not constant over time, Economics Letters, vol.88, issue.3, pp.389-396, 2005. ,
Safety of medical interventions in children versus adults, Pediatrics, vol.133, issue.3, pp.666-673, 2014. ,
Waiting times and socioeconomic status: Evidence from England, Social Science & Medicine, vol.74, issue.9, pp.1331-1341, 2012. ,
Modes d'accès aux spécialistes en 2006 etévolution depuis la réforme de l'assurance maladie: Enquêtes santé protection sociale 2004 et 2006. Questions d'économie de la santé, pp.1-8, 2008. ,
Practical procedures to deal with common support problems in matching estimation, Econometric Reviews, vol.96, pp.1-15, 2017. ,
The effect of disability on labour market outcomes in Germany: The effects of matching, centre for economic policy research, 2004. ,
Sensitivity of matching-based program evaluations to the availability of control variables, Labour Economics, vol.21, pp.111-121, 2013. ,
The predictive value of self assessed general, physical, and mental health on functional decline and mortality in older adults, Journal of Epidemiology & Community Health, vol.54, issue.2, pp.123-129, 2000. ,
Equality of opportunity and luck: Definitions and testable conditions, with an application to income in france, Journal of Public Economics, vol.93, p.163, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01650733
Equality of opportunity and luck: Definitions and testable conditions, with an application to income in France, Journal of Public Economics, vol.93, pp.1189-1207, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01650733
Equality of Opportunity: How to encompass Fifty Shades of Luck. Working Papers 394, ECINEQ, Society for the Study of Economic Inequality, p.162, 2016. ,
Does more education lead to better health habits? Evidence from the school reforms in Australia, Social Science & Medicine, vol.127, pp.83-91, 2015. ,
The allocation of publicly funded biomedical research, Medical Care Output and Productivity, p.156, 2001. ,
The effect of new drugs on mortality from rare diseases and HIV, p.203, 2001. ,
Pharmaceutical innovation and the burden of disease in developing and developed countries, Journal of Medicine and Philosophy, vol.30, issue.6, pp.663-690, 2005. ,
The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, The European Journal of Health Economics, vol.14, issue.1, p.212, 1999. ,
The impact of pharmaceutical innovation on longevity and medical expenditure in France, Economics & Human Biology, vol.13, pp.107-127, 2000. ,
Pharmaceutical innovation and longevity growth in 30 developing and highincome countries, Health Policy and Technology, vol.3, issue.1, pp.36-58, 2000. ,
The impact of public and private research support on premature cancer mortality and hospitalization in the US, p.213, 1999. ,
The impact of public and private research on premature cancer mortality and hospitalization in the United States, The American Economist, vol.129, p.213, 1999. ,
The long-run impact of new medical ideas on cancer survival and mortality, Economics of Innovation and New Technology, vol.213, pp.1-19, 2018. ,
Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as" equipment for your health, p.153, 2002. ,
Does misery love company? evidence from pharmaceutical markets before and after the orphan drug act, National Bureau of Economic Research, vol.124, p.202, 2003. ,
Caractéristiques et modalités de prise en charge des patients présentant un trouble bipolaire en france: enquête montra, L'Encéphale, vol.39, issue.3, pp.212-223, 2013. ,
Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study, PloS One, vol.13, issue.4, p.202, 2018. ,
Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases? Health Policy, vol.31, p.50, 2018. ,
Factors affecting the uptake of new medicines: A systematic literature review, BMC Health Services Research, vol.14, issue.1, pp.469-214, 2014. ,
Consumerism, reflexivity and the medical encounter, Social Science & Medicine, vol.45, issue.3, pp.373-381, 1997. ,
Rare diseases and effective treatments: Are we delivering? The Lancet, vol.385, p.44, 2015. ,
Outrageous prices of orphan drugs: A call for collaboration, The Lancet, vol.392, p.202, 2018. ,
Life course impacts of parenting a child with a disability, American journal on Mental Retardation, vol.106, issue.3, pp.265-286, 2001. ,
Self-rated health and limiting longstanding illness: interrelationships with morbidity in early adulthood, International Journal of Epidemiology, vol.30, issue.3, pp.600-607, 2001. ,
Economic analysis of social interactions, Journal of Economic Perspectives, vol.14, issue.3, pp.115-136, 2000. ,
Social determinants of health inequalities, The Lancet, vol.365, issue.9464, p.42, 2005. ,
The perceived impact of child care costs on women's labor supply and fertility, Demography, vol.29, issue.4, pp.523-543, 1992. ,
The NICE cost-effectiveness threshold, 2008. ,
, Pharmacoeconomics, vol.26, issue.9, p.251
Orphan drugs and the NHS: Should we value rarity?, BMJ: British Medical Journal, vol.331, issue.7523, 2005. ,
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis, Annals of Neurology, vol.50, issue.1, pp.121-127, 2001. ,
The rule of rescue, Social Science & Medicine, vol.56, issue.12, pp.2407-2419, 2003. ,
Prioritarianism and the measure of utility, Journal of Political Philosophy, vol.23, issue.1, pp.1-22, 2013. ,
Self rated health as a predictor of coronary heart disease in Copenhagen, Denmark, Journal of Epidemiology & Community Health, vol.50, issue.4, pp.423-428, 1996. ,
Citizens and rationing: Analysis of a European survey, Health Policy, vol.49, issue.1-2, pp.75-135, 1999. ,
The value of health and longevity, Journal of Political Economy, vol.114, issue.5, pp.871-904, 2006. ,
The health of caregivers for children with disabilities: Caregiver perspectives. Child: Care, Health and Development, vol.33, pp.180-187, 2007. ,
Modeling longitudinal count data: Testing for group differences in growth trajectories using average marginal effects, Sociological Methods & Research, vol.41, issue.3, pp.467-487, 2012. ,
Challenges in research and health technology assessment of rare disease technologies: report of the ispor rare disease special interest group, Value in Health, vol.21, issue.5, p.45, 2018. ,
, Guide to the methods of technology appraisal. London: Nice, p.244, 2004.
, Changes to NICE drug appraisals: What you need to know, p.247, 2017.
Explicating caregiving by mothers of children with complex needs in Ireland: A phenomenological study, Journal of Pediatric Nursing, vol.27, issue.6, pp.642-651, 2012. ,
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries, The European Journal of Health Economics, vol.18, issue.6, p.48, 2017. ,
The evolving concept of health literacy, Social Science & Medicine, vol.67, issue.12, pp.2072-2078, 2008. ,
Advancing health literacy: A global challenge for the 21st century, vol.59, 2000. ,
Health differences between European countries, Social Science & medicine, vol.64, issue.8, pp.1665-1678, 2007. ,
Estimating average and local average treatment effects of education when compulsory schooling laws really matter, The American Economic Review, vol.96, issue.1, pp.152-175, 2006. ,
The productivity crisis in pharmaceutical R&D, Nature Reviews Drug Discovery, vol.10, issue.6, 2011. ,
Recent amendments to NICE's value-based assessment of health technologies: Implicitly inequitable? Taylor & Francis, vol.156, p.157, 2017. ,
Some inconsistencies in NICE's consideration of social values, Pharmacoeconomics, vol.32, issue.11, 2014. ,
The rise in chronic conditions among infants, children, and youth can be met with continued health system innovations, vol.33, pp.2099-2105, 2014. ,
Effects of risk and time preference and expected longevity on demand for medical tests, Journal of Risk and Uncertainty, vol.28, issue.1, p.69, 2004. ,
The burden of chronic disease in Europe. Caring for People with Chronic Conditions. A Health Systems Perspective, vol.84, pp.15-42, 2008. ,
Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross sectional study, BMJ, vol.344, 2012. ,
Bowling alone: America's declining social capital, Journal of Democracy, vol.6, issue.1, p.61, 1995. ,
Education and Social Capital, National Bureau of Economic Research, vol.62, 1999. ,
L'évaluationéconomique des produits de santé innovants: quelle interprétation pour quel usage? Revue française des affaires sociales, vol.243, pp.263-281, 2016. ,
Accurate representation of patients' opinions for decision-making: Are online health communities good candidates? Diabetes, vol.2, p.66, 2017. ,
Early access schemes and pricing strategies: A case study on temporary authorization for use in France from, Revue française des affaires sociales, vol.258, pp.69-89, 1994. ,
URL : https://hal.archives-ouvertes.fr/halshs-02096440
). (In)-equality in the allocation of R&R resources for rare diseases, Social Justice Research, vol.36, pp.1-41, 2019. ,
Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: A review, European Journal of Cancer, vol.43, issue.17, pp.2467-2478, 2007. ,
Social heuristics and social roles: Intuition favors altruism for women but not for men, Journal of Experimental Psychology: General, vol.145, issue.4, pp.389-97, 2016. ,
Patients' diagnosis decisions in Alzheimer's disease: The influence of family factors, Social Science & Medicine, vol.118, pp.9-16, 2014. ,
National Institute for Clinical Excellence and its value judgments, BMJ: British Medical Journal, vol.329, issue.7459, p.246, 2004. ,
Parenting and childhood chronicity: Making visible the invisible work, Journal of Pediatric Nursing, vol.17, issue.6, pp.424-438, 2002. ,
Risky families: Family social environments and the mental and physical health of offspring, Psychological Bulletin, vol.128, issue.2, 2002. ,
Delays in diagnosis and melanoma prognosis (i): The role of patients, International Journal of Cancer, vol.89, issue.3, pp.271-279, 2000. ,
Influence of delay on survival in patients with breast cancer: A systematic review, The Lancet, vol.353, issue.9159, pp.1119-1126, 1999. ,
, , 2015.
, Rare disease terminology and definitions-A systematic global review: Report of the ISPOR rare disease special interest group, Value in Health, vol.18, issue.6, p.45
Income and employment effects of health shocks: A test case for the German welfare state, Journal of Population Economics, vol.12, issue.3, pp.363-389, 1999. ,
The empirics of social capital and health. The Economics of Social Capital and Health: A Conceptual and Empirical Roadmap, p.61, 2014. ,
From social capital to health-and back, Health economics, vol.23, issue.5, p.61, 2014. ,
Asymétries d'information et incertitude en santé: les apports de la théorie des contrats, Economie & prévision, vol.129, issue.3, pp.11-24, 1997. ,
Rare disease policies to improve care for patients in Europe, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol.1852, issue.10, p.118, 2015. ,
Equality of Opportunity. Cambridge, vol.162, p.171, 1998. ,
URL : https://hal.archives-ouvertes.fr/hal-01456129
Who shall not be treated: Public attitudes on setting health care priorities by person-based criteria in 28 nations, PloS one, vol.11, issue.6, 2016. ,
The central role of the propensity score in observational studies for causal effects, Biometrika, vol.70, issue.1, pp.41-55, 1983. ,
Reducing bias in observational studies using subclassification on the propensity score, Journal of the American Statistical Association, vol.79, issue.387, pp.516-524, 1984. ,
Combining propensity score matching with additional adjustments for prognostic covariates, Journal of the American Statistical Association, vol.95, issue.450, pp.573-585, 2000. ,
The role of social capital in reducing nonspecific psychological distress: The importance of controlling for omitted variable bias, Social Science & Medicine, vol.65, issue.4, pp.842-854, 2007. ,
Toward an ontological treatment of disease and diagnosis, Summit on translational bioinformatics, vol.24, p.40, 2009. ,
Why rare diseases are an important medical and social issue, The Lancet, vol.371, issue.9629, p.152, 2008. ,
Short-and medium-term effects of informal care provision on female caregivers' health, Journal of Health Economics, vol.42, pp.174-185, 2015. ,
Chapter Twelve -Markets for Pharmaceutical Products, Handbook of Health Economics, vol.2, p.152, 2011. ,
Handbook of parametric and nonparametric statistical procedures, p.161, 2003. ,
Physicians' perception of demand-induced supply in the information age: A latent class model analysis, Health Economics, vol.21, issue.3, pp.252-269, 2012. ,
Pricing and reimbursement of orphan drugs: The need for more transparency, Orphanet Journal of Rare Diseases, vol.6, issue.1, p.50, 2011. ,
Exploring patient involvement in healthcare decision making across different education and functional health literacy groups, Social Science & Medicine, vol.69, issue.12, pp.1805-1812, 2009. ,
Ensuring value for money in health care: The role of health technology assessment in the European Union. Number 11. WHO Regional Office Europe, vol.31, p.48, 2008. ,
The economic costs of childhood disability. The Future of Children, vol.85, pp.65-96, 2012. ,
Health technology funding decisionmaking processes around the world, Pharmacoeconomics, vol.29, issue.6, pp.475-495, 2011. ,
Reconciliation of economic concerns and health policy, Pharmacoeconomics, vol.22, issue.17, pp.1097-1107, 2004. ,
The challenge of rare diseases, Chest, vol.153, issue.6, p.45, 2018. ,
Delay in diagnosis of ?1-antitrypsin deficiency: A continuing problem, Chest, vol.128, issue.4, p.45, 2005. ,
Physical and social impact of alpha 1-antitrypsin deficiency: Results of a survey, Cleveland Clinic Journal of Medicine, vol.61, issue.6, p.45, 1994. ,
The effect of health shocks on smoking and obesity, The European Journal of Health Economics, vol.13, issue.4, pp.451-460, 2012. ,
EQ-5D value sets: Inventory, comparative review and user guide, vol.2, p.240, 2007. ,
Emotional intensity predicts autobiographical memory experience, Memory & Cognition, vol.32, issue.7, pp.1118-1132, 2004. ,
Symptom and airflow correlates of delayed diagnosis in alpha-1 antitrypsin deficiency, Chest, vol.152, issue.4, p.45, 2017. ,
Equality, priority or what?, Economics and Philosophy, vol.19, issue.1, p.156, 2003. ,
Taking redistributive principles into account in the economic evaluation of health care: A review of available methods. Revue française des affaires sociales, vol.156, pp.169-191, 2017. ,
Cost-effectiveness thresholds: The past, the present and the future, PharmacoEconomics, vol.244, pp.1-14, 2018. ,
Clarifying meanings of absolute and proportional shortfall with examples. Office of Health Economics, vol.17, p.247, 2013. ,
Cost-effectiveness thresholds: Economic and ethical issues. King's Fund, p.245, 2002. ,
Inequality of opportunities in health in France: A first pass, Health Economics, vol.19, issue.8, pp.921-938, 2010. ,
Évaluationéconomique des technologies de santé du nice: un regard expert. Les Tribunes de la santé, p.241, 2010. ,
Long-term effect of teenage birth on earnings: Evidence from a British cohort study, Oxford Economic Papers, vol.69, issue.3, pp.758-781, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01700752
Mediating role of education and lifestyles in the relationship between early-life conditions and health: Evidence from the 1958 British cohort, Health Economics, vol.21, pp.129-150, 2012. ,
Parental health spillover in cost-effectiveness analysis: Evidence from self-harming adolescents in england, PharmacoEconomics, vol.37, issue.4, p.44, 2019. ,
On the estimation of the cost-effectiveness threshold: Why, what, how? Value in Health, vol.19, p.241, 2016. ,
The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Special situations, Journal of Crohn's and Colitis, vol.4, issue.1, pp.63-101, 2010. ,
Dynamics of obesity and chronic health conditions among children and youth, Jama, vol.303, issue.7, pp.623-630, 2010. ,
Voice and equality: Civic voluntarism in American politics, p.62, 1995. ,
A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity, Medical Care, vol.34, issue.3, pp.220-233, 1996. ,
The mos 36-item short-form health survey (sf-36): I. conceptual framework and item selection, Medical care, vol.87, pp.473-483, 1992. ,
Foundations of cost-effectiveness analysis for health and medical practices, New England Journal of Medicine, vol.296, issue.13, pp.716-721, 1977. ,
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy, vol.95, pp.216-228, 2010. ,
, Social determinants of health, WHO, vol.26, p.42, 2008.
Social determinants of health: The solid facts. World Health Organization, vol.26, p.42, 2003. ,
Socio-economic status of the patient and doctor-patient communication: Does it make a difference?, Patient Education and Counseling, vol.56, issue.2, pp.139-146, 2005. ,
Intergenerational equity: An exploration of the 'fair innings' argument, Health Economics, vol.6, issue.2, pp.117-132, 1997. ,
The rationing debate. Rationing health care by age: The case for, BMJ, vol.314, issue.7083, 1997. ,
Equity in health, Handbook of Health Economics, vol.1, pp.1863-1910, 2000. ,
How illness affects family members: A qualitative interview survey. The Patient-Patient-Centered Outcomes Research, vol.6, pp.257-268, 2013. ,
Social and nonmarket benefits from education in an advanced economy, Conference Series -Federal Reserve Bank of Boston, vol.47, p.60, 1998. ,
Estimation of clinical trial success rates and related parameters, Biostatistics, vol.20, issue.2, p.138, 2019. ,
The relationship between selfrated health and objective health status: A population-based study, BMC Public Health, vol.13, issue.1, pp.320-87, 2013. ,
The global burden of chronic diseases: Overcoming impediments to prevention and control, Jama, vol.291, issue.21, p.44, 2004. ,
Market incentives and pharmaceutical innovation, Journal of Health Economics, vol.27, issue.4, p.202, 2008. ,